Lexeo Therapeutics (LXEO) Current Assets (2022 - 2026)

Lexeo Therapeutics has reported Current Assets for 5 years, with the latest figure at $200.9 million in Q1 2026.

• Quarterly Current Assets rose 90.8% year-over-year to $200.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200.9 million (up 90.8% YoY) and the FY2025 annual result came in at $188.4 million, up 49.37% from the prior year.
• Current Assets advanced to $200.9 million in Q1 2026 per LXEO's latest filing, from $188.4 million in the prior quarter.
• Over five years, Current Assets peaked at $200.9 million in Q1 2026 and troughed at $38.9 million in Q3 2023.
• A 5-year average of $138.9 million and a median of $133.9 million in 2025 frame the typical range for Current Assets.
• The sharpest annual moves came in 2024 and 2025: Current Assets surged 310.19% in 2024, then slumped 46.86% in 2025.
• Over 5 years, Current Assets stood at $80.0 million in 2022, then surged by 55.27% to $124.3 million in 2023, then grew by 1.47% to $126.1 million in 2024, then surged by 49.37% to $188.4 million in 2025, then rose by 6.62% to $200.9 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $200.9 million, $188.4 million, and $127.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.